Gastroenterology
Systematic Review: Antibiotics for uncomplicated diverticulitis.
27 Jun, 2022 | 11:56h | UTCAntibiotics for uncomplicated diverticulitis – Cochrane Library
Summary: Antibiotics for uncomplicated diverticulitis – Cochrane Library
Related:
Efficacy and Safety of Non-Antibiotic Outpatient Treatment in Mild Acute Diverticulitis (DINAMO-study): A Multicentre, Randomised, Open-Label, Non-Inferiority Trial – Annals of Surgery (link to abstract – $ for full-text)
Elective surgical management of diverticulitis – Current Problems in Surgery
Management of Colonic Diverticulitis – Agency for Healthcare Research and Quality
Commentary on Twitter
The benefits of antibiotics in diverticulitis are uncertain with respect to complications, emergency✂️, recurrence, elective colonic resections&long‐term complications. This may be because diverticulitis is❌an infectious disorder, but an inflammatory onehttps://t.co/0HmAllw5Af
— John Damianos, M.D. (@john_damianosMD) June 26, 2022
Phase 2 single-arm study: Fazirsiran for liver disease associated with Alpha1-Antitrypsin deficiency.
27 Jun, 2022 | 11:19h | UTCFazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In this small trial in adults with ATT deficiency, fazirsiran was associated with a strong reduction of mutant AAT levels in the serum and liver and concurrent improvements in liver enzyme levels. #ILC2022 https://t.co/RibsKzOQfO pic.twitter.com/BnMcSyfVcq
— NEJM (@NEJM) June 25, 2022
Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.
27 Jun, 2022 | 11:17h | UTCCommentary: Chronic Hepatitis B Infections Decreasing in Recent Years – HCP Live
Commentary on Twitter
New research from #GBDStudy – Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019https://t.co/e0oxlT2gKd#hepB #HBV #nohep #livertwitter @IHME_UW pic.twitter.com/V8h1LrCoUQ
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) June 21, 2022
M-A: Relationship between serum lipid level and colorectal cancer.
27 Jun, 2022 | 11:01h | UTC
ESPGHAN Position Paper: use of low-FODMAP diet in pediatric gastroenterology.
24 Jun, 2022 | 11:15h | UTC
Dysplastic recurrence after successful treatment for early Barrett’s neoplasia: development and validation of a prediction model.
24 Jun, 2022 | 11:07h | UTC
Consensus report on anatomy, pathophysiology and clinical significance of the gastro-esophageal junction.
23 Jun, 2022 | 10:26h | UTC
AGA Guidelines on the pharmacological management of irritable bowel syndrome.
23 Jun, 2022 | 10:24h | UTCPart 1: Patients with diarrhea: AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea – Gastroenterology
Part 2: Patients with constipation: AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation – Gastroenterology
Commentary: AGA issues guidance on drug treatment for patients with IBS – ACP Gastroenterology
Commentary on Twitter
Clinical decision support tool from the @AmerGastroAssn for #IBS based on the most recent evidence.
💩IBS-C: https://t.co/OeswowXhIP
💩IBS-D: https://t.co/4W8PbpV4b0
🔦Spotlight on IBS treatment: https://t.co/oxZfD3m8u5#MedTwitter #GITwitter #DGBI #FGID #motility pic.twitter.com/eiMqCdS8js
— John Damianos, M.D. (@john_damianosMD) June 22, 2022
RCTs: Risankizumab as induction therapy for Crohn’s disease.
23 Jun, 2022 | 10:02h | UTCRisankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials – The Lancet (link to abstract – $ for full-text)
Related: Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
In patients with moderately to severely active Crohn's disease, risankizumab was effective and well tolerated as induction therapy, studies indicate.
Find out more: https://t.co/zg70L8RYka #crohnsdisease pic.twitter.com/9evGJAH8ke
— The Lancet (@TheLancet) June 1, 2022
Guideline review: EASL clinical practice guidelines: drug-induced liver injury.
22 Jun, 2022 | 11:27h | UTCOriginal Article: EASL Clinical Practice Guidelines: Drug-induced liver injury – Journal of Hepatology
RCT: Multispecies probiotic for the prevention of antibiotic-associated diarrhea in children.
22 Jun, 2022 | 11:12h | UTCMultispecies Probiotic for the Prevention of Antibiotic-Associated Diarrhea in Children: A Randomized Clinical Trial – JAMA Pediatrics (free for a limited period)
Commentary: Mixed Results With Probiotic for Kids’ Antibiotic-Related Diarrhea— Randomized trial misses strictly defined endpoint, but researchers point to benefit – MedPage Today (free registration required)
Commentary on Twitter
Study found administration of a multispecies #probiotic to children had no significant effect on the risk of antibiotic-associated diarrhea caused by #Cdifficile or of unknown etiology, but reduced the overall risk of diarrhea regardless of the etiology. https://t.co/Mdq3tl8csb
— JAMA Pediatrics (@JAMAPediatrics) June 21, 2022
Cohort Study: Association of gamma-glutamyltransferase levels with total mortality, liver-related and cardiovascular outcomes.
20 Jun, 2022 | 10:36h | UTC
Commentary on Twitter
Still remember working on this in 2019 but it's out today!
Gamma-GT level has a strong association with mortality outcomes and could add to the prediction of CV mortality
https://t.co/0lzqGfgiGc pic.twitter.com/C8tSZLWlI2— Fred Ho (@fredho42) May 13, 2022
Under a CC BY-NC-ND 4.0 license
RCT: Immune enhancement with Thymosin alpha 1 does not improve outcomes in patients with predicted severe acute necrotizing pancreatitis.
20 Jun, 2022 | 01:11h | UTCImmune enhancement in patients with predicted severe acute necrotising pancreatitis: a multicentre double-blind randomised controlled trial – Intensive Care Medicine (if the link is paywalled, try this one)
Consensus Recommendations: Nomenclature and diagnosis of seronegative coeliac disease and chronic non-coeliac enteropathies in adults.
15 Jun, 2022 | 10:58h | UTC
RCT: Discontinuation of Infliximab therapy in patients with Crohn’s disease.
15 Jun, 2022 | 10:54h | UTCDiscontinuation of Infliximab Therapy in Patients with Crohn’s Disease – NEJM Evidence
RCT: Vonoprazan triple and dual therapy for Helicobacter pylori infection.
15 Jun, 2022 | 10:41h | UTCVonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the US and Europe: Randomized Clinical Trial – Gastroenterology (link to abstract – $ for full-text)
Encephalopathy in cirrhosis: prevention and management.
15 Jun, 2022 | 10:39h | UTC
Review: Portal vein thrombosis in cirrhosis.
15 Jun, 2022 | 10:38h | UTCPortal Vein Thrombosis in Cirrhosis – Journal of Clinical and Experimental Hepatology
Review: Value of liver function tests in cirrhosis.
15 Jun, 2022 | 10:35h | UTCValue of Liver Function Tests in Cirrhosis – Journal of Clinical and Experimental Hepatology
Guideline: Functional bowel disorders with diarrhea.
14 Jun, 2022 | 11:20h | UTC
Position Paper: Diagnostic therapeutic care pathway for pediatric food allergies and intolerances.
14 Jun, 2022 | 11:05h | UTC
ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility.
14 Jun, 2022 | 10:59h | UTCCommentary: New guidelines for pancreatic cancer screening – Beth Israel Deaconess Medical Center
Commentary on Twitter
Sawhney et al share "ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations." https://t.co/P6OtmhXr2D pic.twitter.com/vDHWfKCAiN
— GIE (@GIE_Journal) May 26, 2022
Podcast: Gallbladder disease pearls.
14 Jun, 2022 | 10:46h | UTC#340 Gallbladder Disease – The Curbsiders
Case Series | Outbreak of hepatitis in children: clinical course of children with acute liver failure admitted to the intensive care unit.
13 Jun, 2022 | 10:46h | UTCOutbreak of hepatitis in children: clinical course of children with acute liver failure admitted to the intensive care unit – Intensive Care Medicine (if the link is paywalled, try this one)
Related: Investigating acute hepatitis of unknown origin in children (several resources on the subject)
Commentary on Twitter
Outbreak of non-A-E hepatitis in children, 🇬🇧 data. Good outcomes if ALF by dedicated liver #ICU with early referral to Tx centres, recognizing neuro-deterioration, high-volume #ECLS, close neuromonitoring/protection & support by hepatology/Tx physicians
📎https://t.co/GYAMaZbVGD pic.twitter.com/GA58vJWQIz— Intensive Care Medicine (@yourICM) June 10, 2022
RCT: Ustekinumab vs. adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease.
13 Jun, 2022 | 07:56h | UTCUstekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
New @TheLancet – Sands et al – Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease (SEAVUE trial)https://t.co/Ov9ahRTQuC#IBD #GITwitter #Crohnsdisease pic.twitter.com/5f3vI6rRKd
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) June 10, 2022